What are Biohaven's total assets?

Biohaven (BHVN) holds $466.4M in total assets, up 1.6% year over year.

How much debt does Biohaven have?

Biohaven carries $286.2M in total debt against $129.5M of shareholders' equity, a debt-to-equity ratio of 2.21.

How much cash does Biohaven have?

Biohaven holds $277.1M in cash and equivalents.

Can Biohaven cover its short-term obligations?

Its current ratio is 7.41 — current assets exceed current liabilities.

Where does Biohaven's balance sheet data come from?

Every line is extracted from Biohaven's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Biohaven BHVN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$277.11M+170%	$232.78M+127%	$188.38M+114%	$169M-30.3%	$102.69M-45.1%
Short-term investments	$74.74M-66.7%	$89.18M-76.9%	$75.37M-74.4%	$239.18M+20.9%	$224.33M+123%
Restricted cash	——	——	——	——	——
Prepaid expenses and other current assets	$198.16M-10.1%	$219.88M+4.6%	$222.24M+13.3%	$222.42M+27.2%	$220.47M+54.1%
Total current assets	$385.65M+0.8%	$368.33M-31.6%	$323.62M-26.5%	$474.83M-7.1%	$382.76M+9.8%
Property and equipment, net	$15.26M-14.2%	$15.96M-7.8%	$17.52M-4.1%	$18.59M-0.4%	$17.79M+6.6%
Accumulated depreciation	$16.83M+27.3%	$16.13M+32.1%	$15.39M+37.4%	$14.28M+40.0%	$13.22M+43.3%
Operating lease right-of-use assets	$43.4M+22.5%	$45.06M+23.8%	$45.2M+56.4%	$34.24M+14.5%	$35.43M+14.7%
Goodwill	$1.39M0.0%	$1.39M0.0%	$1.39M0.0%	$1.39M0.0%	$1.39M0.0%
Intangible assets, net	$18.4M0.0%	$18.4M0.0%	$18.4M0.0%	$18.4M0.0%	$18.4M0.0%
Other non-current assets	$2.31M-27.3%	$2.31M-26.4%	$3M-1.7%	$2.96M-1.7%	$3.18M+31.0%
Available-for-sale securities	$150.53M—	$114.11M—	$75.34M—	——	——
Allowance for credit losses	$0—	$0—	$0—	——	——
Total assets	$466.41M+1.6%	$451.45M-26.6%	$409.12M-19.9%	$550.42M-5.5%	$458.95M+9.7%
Accounts payable	$59.18M-20.2%	$67.9M-25.7%	$74.29M-16.5%	$76.54M-2.8%	$74.17M+0.9%
Accrued expenses	$4.43M-32.1%	$16.78M-67.4%	$18.2M+14.6%	$12.11M+11.7%	$6.53M+21.1%
Operating lease liabilities, current	$5.9M+25.3%	$5.76M+51.4%	$5.51M+49.9%	$4.7M+32.3%	$4.71M—
Total current liabilities	$52.08M-68.3%	$115.93M-24.8%	$113.02M-25.8%	$124.32M-20.4%	$164.03M+89.4%
Long-term debt	$241.91M—	——	——	——	——
Operating lease liabilities, non-current	$38.36M+24.5%	$39.96M+21.9%	$40.39M+59.6%	$29.8M+13.8%	$30.8M+13.7%
Other non-current liabilities	$4.56M-1.2%	$4.58M-1.7%	$4.6M+0.1%	$4.64M+7.3%	$4.61M+35.2%
Total liabilities	$336.91M+68.9%	$399.38M+108%	$426.28M+119%	$415.83M+109%	$199.45M+70.3%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	200M0.0%	200M-87.9%	200M0.0%	200M0.0%	200M0.0%
Additional paid-in capital	$203.36M+47.9%	$193.98M+72.6%	$178.05M+91.4%	$157.02M+87.3%	$137.47M+98.1%
Retained earnings	-$2.22B-41.3%	-$2.08B-54.9%	-$1.94B-67.3%	-$1.77B-76.8%	-$1.57B-131%
Accumulated other comprehensive income (loss)	$8.3M+11,273%	$8.35M+10,467%	$36K-74.3%	-$3K+96.2%	$73K+169%
Total stockholders' equity	$129.5M-50.1%	$52.07M-87.7%	-$17.16M-105%	$134.59M-64.9%	$259.5M-13.9%
Total liabilities and stockholders' equity	$466.41M+1.6%	$451.45M-26.6%	$409.12M-19.9%	$550.42M-5.5%	$458.95M+9.7%
Available-for-Sale Debt Securities - Amortized Cost	$150.53M—	$114.11M—	$75.34M—	——	——
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	$150.53M-32.9%	$114.11M-70.5%	$75.34M-74.4%	$308.94M+31.6%	$224.29M+106%
Available-for-Sale Debt Securities - Amortized Cost (<1 Year)	$150.53M-32.9%	$114.11M-70.5%	$75.34M-74.4%	$308.94M+31.6%	$224.29M+106%
Available-for-Sale Debt Securities - Fair Value (Maturing Within 1 Year)	$150.52M-32.9%	$114.17M-70.5%	$75.37M-74.4%	$308.92M+31.6%	$224.33M+106%
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	0—	0—	0—	0—	0—
Cash, Cash Equivalents, and Marketable Securities	$150.52M-32.9%	$114.17M-70.5%	$75.37M-74.4%	$308.92M+31.6%	$224.33M+106%
Short- term Investments	$74.74M-66.7%	$89.18M-76.9%	$75.37M-74.4%	$239.18M+20.9%	$224.33M+123%
Other current assets	$3.17M-12.5%	$2.17M-30.1%	$8.42M+602%	$8.36M+15.0%	$3.62M-66.1%
Deferred Tax Assets and Other Non-Current Assets	$45.71M+18.4%	$47.36M+19.8%	$48.2M+50.8%	$37.21M+13.0%	$38.61M+15.9%
Investments - Amortized Cost Basis	$150.53M—	$114.11M—	$75.34M—	——	——
Net Investment in Lease	$43.4M+22.5%	$45.06M+23.8%	$45.2M+56.4%	$34.24M+14.5%	$35.43M+14.7%
Other intangible assets—net	$18.4M0.0%	$18.4M0.0%	$18.4M0.0%	$18.4M0.0%	$18.4M0.0%
Operating lease right-of-use assets	$43.4M+22.5%	$45.06M+23.8%	$45.2M+56.4%	$34.24M+14.5%	$35.43M+14.7%
Other non-current assets	$45.71M+18.4%	$47.36M+19.8%	$48.2M+50.8%	$37.21M+13.0%	$38.61M+15.9%
Operating Lease Right-of-Use Assets in Other Assets	$43.4M+22.5%	$45.06M+23.8%	$45.2M+56.4%	$34.24M+14.5%	$35.43M+14.7%
Software and Technology Licenses, Net	$45.71M+18.4%	$47.36M+19.8%	$48.2M+50.8%	$37.21M+13.0%	$38.61M+15.9%
Accrued Manufacturing Costs	$4.43M-32.1%	$16.78M+10,797%	$18.2M+14.6%	$12.11M+11.7%	$6.53M+21.1%
Other Commercial Liabilities	$41.65M-26.4%	$104.29M+103%	$73.52M+15.7%	$78.73M+36.4%	$56.57M+12.7%
Accrued Liabilities, Current	$41.65M-26.4%	$104.29M+103%	$73.52M+15.7%	$78.73M+36.4%	$56.57M+12.7%
Compensation and benefits	$4.43M-32.1%	$16.78M+10,797%	$18.2M+14.6%	$12.11M+11.7%	$6.53M+21.1%
Long-Term Debt - Fair Value	——	——	——	——	——
Total debt	$286.18M+706%	$284.61M+678%	$314.18M+984%	$291.56M+880%	$35.51M+16.3%
Common Stock Shares Issued	150.5M+47.4%	132.8M+31.2%	105.8M+11.5%	105.8M+14.5%	102.1M+24.8%
Common Stock Shares Outstanding	——	——	——	——	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2.13B+26.3%	$1.93B+16.8%	$1.74B+26.2%	$1.74B+34.2%	$1.69B+85.4%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Number of Exercisable Options	——	——	——	——	——
Number of Vested and Expected to Vest Options	——	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	20.3M+31.6%	15.6M+22.4%	15.8M+20.7%	15.7M—	15.4M—
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Unrealized Gains on Investments	$2K—	$61K—	$29K—	——	——
Unrealized Losses on Investments (Before Tax)	$3K—	$0—	$0—	——	——
Weighted Average Exercise Price of Outstanding Options	$18.84-11.1%	$21.06+20.6%	$21.11+21.6%	$21.18—	$21.20—
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——	——	——
Cumulative Cost Basis	$150.53M—	$114.11M—	$75.34M—	——	——
Fair Value Measurement Disclosure	——	——	——	——	——
Accrued clinical trial costs	$21.54M-32.9%	$30.44M-20.8%	$36.92M+4.1%	$33.92M-6.9%	$32.11M+0.3%
2025 Additional Consideration True-Up liability	——	——	——	——	——
Additional regulatory milestone payments	——	——	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$3K—	$0—	$0—	——	——
Gross Unrealized Gains	$2K—	$61K—	$29K—	——	——
Total	$150.53M—	$114.11M—	$75.34M—	——	——
1 Year or Less	$150.52M-32.9%	$114.17M-70.5%	$75.37M-74.4%	$308.92M+31.6%	$224.33M+106%
Available for sale investments	$150.52M-32.9%	$114.17M-70.5%	$75.37M-74.4%	$308.92M+31.6%	$224.33M+106%
Common stock, no par value (in dollars per share)	$0.00—	$0.00—	$0.00—	$0.00—	$0.00—
Common stock, shares authorized (in shares)	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%
Common stock, shares issued (in shares)	$150.51M+47.4%	$132.78M+31.2%	$105.8M+11.5%	$105.78M+14.5%	$102.1M+24.8%
Common Stock, Shares, Outstanding	$150.51M+47.4%	$132.78M+31.2%	$105.8M+11.5%	$105.78M+14.5%	$102.1M+24.8%
Debt Instrument, Fair Value Disclosure	——	——	——	——	——
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$0—	$0—	$0—	——	——
Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss	$150.53M—	$114.11M—	$75.34M—	——	——
Number of Securities, Greater than 12 months	$0—	$0—	$0—	$0—	$0—
Unrecognized compensation cost related to non-vested awards	——	——	——	——	——
Long Term Notes Payable	$241.91M—	——	——	——	——
Development milestone payment to be paid	——	——	——	——	——
Commercial milestone payment to be paid	——	——	——	——	——
Milestone payment to be paid upon regulatory achievement	——	——	——	——	——
Aggregate fair value	——	——	——	——	——
Offsetting asset	——	——	——	——	——
Outstanding amounts	——	——	——	——	——
Other accrued liabilities	$9.78M-26.0%	$8.61M-5.4%	$12.89M+51.5%	$12.85M+86.6%	$13.23M+41.2%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Prepaid expenses	$34.67M-38.5%	$47.02M-4.8%	$54.98M-0.3%	$61.49M+3.3%	$56.39M+22.0%
Restricted Cash Included in Other Current Assets	——	——	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$20.31M+31.6%	$15.65M+22.4%	$15.8M+20.7%	$15.67M—	$15.43M—
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$18.84-11.1%	$21.06+20.6%	$21.11+21.6%	$21.18—	$21.2—
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Unvested options expected to vest (in shares)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——
Success-based milestone payments, based on regulatory approval	——	——	——	——	——
Research and development accrual	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Biohaven's total assets?: Biohaven (BHVN) holds $466.4M in total assets, up 1.6% year over year.
How much debt does Biohaven have?: Biohaven carries $286.2M in total debt against $129.5M of shareholders' equity, a debt-to-equity ratio of 2.21.
How much cash does Biohaven have?: Biohaven holds $277.1M in cash and equivalents.
Can Biohaven cover its short-term obligations?: Its current ratio is 7.41 — current assets exceed current liabilities.
Where does Biohaven's balance sheet data come from?: Every line is extracted from Biohaven's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.